Alamar Biosciences (ALMR) COO receives RSUs, major option grant
Rhea-AI Filing Summary
Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.
The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class A Common Stock | 247,311 | $0.00 | $0.00 |
| Conversion | Founders Preferred Stock | 73,200 | $0.00 | $0.00 |
| Conversion | Series A-1 Preferred Stock | 176,160 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 300,883 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 300,883 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 12,190 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 12,190 | $0.00 | $0.00 |
| Conversion | Class B Common Stock | 320,511 | $0.00 | $0.00 |
| Conversion | Class B Common Stock | 72,853 | $0.00 | $0.00 |
| Other | Class B Common Stock | 722,885 | $0.00 | $0.00 |
| Other | Common Stock | 722,885 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 37,220 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 163,358 | $0.00 | $0.00 |
Footnotes (7)
- F1. The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
- F2. The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
- F3. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
- F4. Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
- F5. Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
- F6. The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
- F7. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
Class B Common Stock financial
Series A-1 Preferred Stock financial
Founders Preferred Stock financial
initial public offering financial
stock option (Right to Buy) financial
AI-generated analysis. How Rhea-AI works. Not financial advice.